Pregabalin Capsule
Product Images NDC 82804-049

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 82804-049). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 01)

A line graph depicting percent improvement versus percent of patients, comparing Pregabalin 25 mg given once daily and three times daily, along with placebo groups. The graph illustrates patient response over a range of improvement percentages.*

FDA Label Image

Figure 2 (Image 02)

A line chart comparing the percent improvement in pain from baseline with pregabalin 150 mg given twice daily versus placebo. The x-axis represents percent improvement in pain, and the y-axis shows the percent of subjects with pain response. Pregabalin shows a higher percentage of pain responders across improvement levels.*

FDA Label Image

Figure 3 (Image 03)

A line chart illustrating the percent improvement in pain score on the x-axis against the percent of patients on the y-axis for different dosages of Pregabalin (25 mg, 150 mg, 300 mg, and 600 mg taken three times a day). The chart shows a comparative distribution of pain improvement across these doses.*

FDA Label Image

Figure 4 (Image 04)

A line graph comparing the percent improvement from baseline between Pregabalin 250 mg three times a day and Pregabalin 150 mg three times a day over a time period of 0 to 240 days. The vertical axis represents percent improvement from baseline, while the horizontal axis shows time in days.*

FDA Label Image

Figure 5 (Image 05)

Line graph depicting the percent of patients remaining without an event over time in days, comparing Pregabalin 150 mg twice daily, Pregabalin 300 mg twice daily, and placebo groups. The x-axis represents the percentage improvement in pain score, while the y-axis shows the percent of patients remaining without event.*

FDA Label Image

Figure 6 (Image 06)

This chart presents responder rates (%) from two separate studies labeled Study E1 and Study E3. It compares different dosages of a treatment against placebo for responder rates. The X-axis shows dosages in mg/day including placebo, and the Y-axis shows responder rate percentages from 0% to 60%. Statistically significant differences versus placebo are indicated with an asterisk.*

FDA Label Image

Figure 7 (Image 07)

A scatter plot graph showing the relationship between dose (mg/kg) on the x-axis and mean Cmax (ng/mL) on the y-axis. The graph includes multiple data points connected by curves representing different studies labeled Study 4 E10D, Study 5 E10D, Study 3 E10D, Study 2 E10D, and Study 1 E10D. Each study is represented by different symbols, displaying trends in concentration following oral dosing.*

FDA Label Image

Figure 8 (Image 08)

A bar chart showing responder rates (%) for three groups: Placebo (22.6%), 2.5 mg/kg/day (29.1%), and 10 mg/kg/day (40.6%). The chart includes sample sizes below each group: 93 for Placebo, 103 for 2.5 mg/kg/day, and 96 for 10 mg/kg/day.*

FDA Label Image

Figure 10 (Image 09)

A line graph comparing the estimated percentage of subjects without LTR (loss to response) over 180 days between Pregabalin and placebo groups. The x-axis represents days, and the y-axis shows the estimated percentage without LTR, ranging from 0% to 100%. Two lines depict outcomes, with Pregabalin consistently showing higher percentages than placebo throughout the period.*

FDA Label Image

Figure 11 (Image 10)

A line chart depicting percent improvement from baseline to week 12 by dose for Pregabalin capsules 25 mg and placebo. The y-axis shows percent improvement, while the x-axis indicates time in days from baseline to week 12. The chart compares two groups: Pregabalin and placebo, illustrating changes in percent improvement over time.*

FDA Label Image

Figure 12 (Image 11)

A line graph comparing percent oocytes with GABA-activated current over prolonged incubation times (in minutes) for two substances: Pregabalin and Placebo. The x-axis represents incubation time, and the y-axis shows the percentage of oocytes with current, illustrating a decline over time for both groups.*

FDA Label Image

Figure 9 (Image 12)

A line graph depicting percent improvement in pain from baseline on the x-axis compared to the percent of patients improved on the y-axis. The graph compares four groups: Pregabalin 800 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo, each represented by distinct line styles. Vertical lines highlight percent improvement thresholds at 30% and 50%.*

FDA Label Image

82804-049-60 (Pregabalin Caps 25mg 30ct)

Label for Pregabalin 25 mg capsules, 60 count, manufactured by ScieGen Pharmaceuticals, Inc. The capsules are white to off-white gelatin hard capsules with white opaque cap and body, imprinted with "SG" on cap and "350" on body in black ink. The product is packaged by Proficient Rx LP and labeled for oral use with NDC 82804-049-60. It is a Schedule V controlled substance (C-V) and for prescription use only.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A mathematical formula for calculating creatinine clearance (CLcr) based on age, weight, serum creatinine, and gender adjustment. It shows the equation with age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplier of 0.85 for female patients.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of pregabalin, showing its molecular formula with side chains including an amino group and a carboxyl group. The structure is consistent with the active ingredient in Pregabalin capsules, 25 mg strength.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.